ABSTRACT
Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/- ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable efficacy and safety, whereas the co-infusion of CD19 & CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed.
NOVELTY AND IMPACT Although currently approved CAR T-cells demonstrated unprecedently high response in relapsed / refractory LBCL in the salvage setting, lack of outcome durability and toxicity remain. We delineated the relative clinical benefit of the innovative experimental CAR T-cell approaches to Yescarta for insights into the ongoing efforts to address these inadequacies. Tandem CAR T-cells may provide higher efficacy and safer profile than Yescarta. Toxicity attenuated CAR T-cells present remarkable safety but no Progression-Free Survival (PFS) benefit.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://journal.ppcr.org/index.php/ppcrjournal/article/view/142
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was based on the published data by the eligible clinical trials in this study. Therefore, ethics committee approval or informed consent statement were not required since the study did not involve patients or the public in the design, conduct, reporting, or dissemination plans.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
To update the Title of the manuscript
Data Availability
Individual patient data obtained from the eligible clinical trials analyzed in this study and any materials generated during the study are available and will be released via a material transfer agreement and study protocol, if available.
https://journal.ppcr.org/index.php/ppcrjournal/article/view/142
ABBREVIATIONS
- ASCT
- autologous stem cell transplantation
- B-ALL
- B-cell acute lymphoblastic leukemia
- BCMA
- B-cell maturation antigen
- CAR
- chimeric antigen receptor
- CD
- cluster of differentiation
- ChiCTR
- Chinese clinical trial registry
- CI
- confidence interval
- CR
- complete response
- CRES
- car T cell-related encephalopathy syndrome
- CRR
- complete response rate
- CRS
- cytokine release syndrome
- CRS
- cytokine release syndrome
- DLBCL
- diffuse large B-cell lymphoma
- DOR
- duration of response
- EFS
- event-free survival
- ESS
- effective sample size
- HGBCL
- high-grade B-cell lymphoma
- HR
- hazard ratio
- Hu
- human
- IFN-γ
- interferon-γ
- IL-2
- interleukins-2
- IPD
- individual patient data
- KM
- Kaplan-Meier
- LBCL
- large B-cell lymphoma
- MAIC
- matching adjusted indirect comparisons
- NCT
- national clinical trial
- NHL
- non-Hodgkin lymphoma
- NT
- neurotoxicity
- OR
- odds ratio
- ORR
- objective response rate
- OS
- overall survival
- PFS
- progression free survival
- PH
- proportional hazards
- PPCR
- principles and practice of clinical research
- PRISMA
- preferred reporting items for systematic reviews and meta-analyses
- R/R LBCL
- relapsed/refractory large B-cell lymphoma
- RR
- relative risk
- RS
- Richter’s transformation
- scFv
- single-chain variable fragment
- SD
- stable disease
- TNF-α
- tumor necrosis factor-α
- trDLBCL
- transformed DLBCL
- ZUMA-1
- name of Yescarta clinical trial
